Healthcare Services

Hematologic Malignancies Testing Market Developments and Growth Opportunities Across 2026–2030

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Hematologic Malignancies Testing Market Between 2026 And 2030?

The hematologic malignancies testing market has seen rapid expansion in recent years. Its value is expected to rise from $3.58 billion in 2025 to $4.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.4%. This historical growth can be attributed to several factors including the rising occurrence of hematologic cancers, the broader embrace of molecular diagnostics, the enlargement of diagnostic laboratory networks, an increasing application of CBC and flow cytometry, and better availability of oncology testing services.

The market for hematologic malignancies testing is projected to experience swift expansion over the coming years. This market is anticipated to reach $6.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.2%. This expansion during the forecast timeframe is driven by factors such as a rising need for precision oncology diagnostics, the increasing incorporation of AI-based data interpretation, the broadening scope of companion diagnostics, greater embrace of MRD monitoring, and heightened investments in cutting-edge diagnostic technologies. Key developments foreseen during this period encompass the greater uptake of NGS-based diagnostic testing, a surge in the application of flow cytometry for MRD detection, enhanced integration of molecular and genetic assays, the widening availability of personalized diagnostic profiling, and a stronger emphasis on prompt and precise subtyping.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24234&type=smp

What Key Drivers Are Influencing The Growth Of The Hematologic Malignancies Testing Market?

The increasing number of cancer diagnoses is projected to fuel the expansion of the hematologic malignancies testing market moving forward. Cancer diagnoses entail identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations, including imaging, laboratory tests, and biopsies. The rise in cancer diagnoses stems from improved access to screening programs and increased public awareness, which contributes to earlier detection. Hematologic malignancies testing assists in cancer diagnoses by enabling early identification, accurate classification, and monitoring of blood-related cancers, thereby guiding targeted treatment decisions and enhancing patient outcomes. For instance, according to American Cancer Society, an US-based nonprofit organization, in 2024, over 2 million new cancer cases are diagnosed in the US, representing a 4% increase from previous years. Thus, the growing volume of cancer diagnoses propels growth within the hematologic malignancies testing market.

Which Market Segments Are Examined In The Hematologic Malignancies Testing Market Study?

The hematologic malignancies testing market covered in this report is segmented –

1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type

2) By Product: Kits, Services

3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology

4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication

5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users

Subsegments:

1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)

2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis

3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis

4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis

5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests

Which Market Trends Are Creating New Opportunities In The Hematologic Malignancies Testing Market?

Companies operating in the hematologic malignancies testing market are concentrating on developing innovative diagnostic methods, such as rapid molecular profiling, to offer healthcare providers precise and timely diagnostic tools that enhance early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling serves as a diagnostic strategy that examines a patient’s genetic composition to identify mutations and variations, enabling quicker and more personalized treatment decisions. As an example, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, introduced PanHeme, a next-generation gene sequencing tool specifically designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. This test detects mutations in hundreds of genes in under 72 hours, thereby significantly improving the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.

Who Are The Primary Competitors In The Hematologic Malignancies Testing Market?

Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings

Read the full hematologic malignancies testing market report here:

https://www.thebusinessresearchcompany.com/report/hematologic-malignancies-testing-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Hematologic Malignancies Testing Market?

North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hematologic Malignancies Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24234&type=smp

Browse Through More Reports Similar to the Global Hematologic Malignancies Testing Market 2026, By The Business Research Company

Dermatological Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report

Hematocrit Test Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report

Hematology Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795